Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable Patients
暂无分享,去创建一个
C. Reddy | P. Mazzone | T. Djemil | G. Videtic | K. Stephans | M. Machuzak | S. Gajdos | M. Kolar
[1] C. Yiannoutsos,et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[2] S. Tung,et al. Hypofractionated stereotactic radiotherapy for medically inoperable stage I non-small cell lung cancer--report on clinical outcome and dose to critical organs. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] Y. Onodera,et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. , 2008, International journal of radiation oncology, biology, physics.
[4] T. Guerrero,et al. Pulmonary Function Tests Before and After Stereotactic Radiation of the Lung , 2007 .
[5] J. Bradley,et al. Pulmonary Function Testing After Stereotactic Body Radiation Therapy for Medically Inoperable Patients With Early Stage NSCLC , 2007 .
[6] J. Galvin,et al. Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early Stage Lung Cancer Patients , 2007 .
[7] Jeffrey Bradley,et al. Radiographic Response and Clinical Toxicity Following SBRT for Stage I Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] H. Shirato,et al. Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Lech Papiez,et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Ping Li,et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.
[11] K. Flatmark,et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition , 2006, Radiation oncology.
[12] H. Geinitz,et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC) , 2006, Acta oncologica.
[13] J. Petersen,et al. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency? , 2006, Acta oncologica.
[14] Jan Nyman,et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries , 2006, Acta oncologica.
[15] Masahiro Hiraoka,et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.
[16] Lech Papiez,et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. , 2005, International journal of radiation oncology, biology, physics.
[17] H. M. Deloar,et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. , 2005, International journal of radiation oncology, biology, physics.
[18] C. Ling,et al. Results of a phase I dose‐escalation study using three‐dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma , 2005, Cancer.
[19] Stephanie Frost,et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.
[20] Shinichi Shimizu,et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. , 2003, International journal of radiation oncology, biology, physics.
[21] R. Timmerman,et al. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. , 2002, Chest.
[22] J. Wong,et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. , 2001, International journal of radiation oncology, biology, physics.
[23] G. Sibley. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma , 1998, Cancer.
[24] J. Cleland,et al. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. , 1995, Circulation.
[25] W. Kannel,et al. The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.
[26] K. Johansson,et al. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. , 2006, Lung cancer.
[27] B. Yalcin,et al. Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.
[28] W. Smythe. Treatment of stage I non-small cell lung carcinoma. , 2003, Chest.
[29] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.